UCSD Spinout Antiva Biosciences Gets $22M
socalTECH
MARCH 29, 2017
San Diego biopharmaceuticals spinout targeting treatments for pre-cancerous lesions caused by human papilloma virus (HPV) infection, said it has raised $22M in a Series C funding. Vinzenz Ploerer of Brace Pharma has joined the company's board with the new funding. READ MORE>>.
Let's personalize your content